GSK Urges Conservation Of Coreg, Citing Limited Availability
This article was originally published in The Pink Sheet Daily
Executive Summary
The company will release a "Dear Healthcare Provider" letter that identifies treatment options for patients with mild to moderate heart failure who cannot get their carvedilol prescriptions filled.
You may also be interested in...
Coreg CR Approved; GSK Plans First Quarter 2007 Launch
Micropump technology licensed from French drug delivery firm Flamel modulates release of GSK’s carvedilol over 24 hours.
Coreg CR Approved; GSK Plans First Quarter 2007 Launch
Micropump technology licensed from French drug delivery firm Flamel modulates release of GSK’s carvedilol over 24 hours.
Avandamet sNDA Approved For First-Line Use In Type 2 Diabetics
GlaxoSmithKline’s updated label for the rosiglitazone/metformin combination also includes new data concerning risk in congestive heart failure patients.